

Table SI. Characteristics and treatment of patients in group A.

Patient	Age, years	Sex	Tumor location	Histopathology	T	N	M	Clinical stage	Delayed start of 2nd dose	Dose reduction	Recurrence	RFS, months	OS, months
1	60	F	Ut	SCC	3	1	0	III	None	-	-	45.9 +	45.9 +
2	75	M	Ut	SCC	3	1	0	IV	None	2nd dose: cisplatin 80%	-	39.3 +	39.3 +
3	74	M	Lt Ae	Adeno	3	1	0	III	None	1st and 2nd doses: cisplatin 80%	Lymph nodes, bone	7.7	16.4 +
4	70	M	Lt Ut Mt	SCC	3	1	0	III	None	2nd dose: cisplatin 50%, 5-FU 50%	Lung	3.1	15.1
5	59	M	Mt	SCC	3	2	0	III	None	2nd dose: cisplatin 80%	-	-	6.3
6	75	F	Mt Ut	SCC	3	2	0	III	None	1st dose: cisplatin 50% 2nd dose: cisplatin 80%	Left principal bronchus	10.1	29.9 +
7	67	F	Ut Ce	SCC	3	1	0	III	None	1st and 2nd doses: cisplatin 80%	-	26.0 +	26.0 +
8	62	M	Ut Ce	SCC	3	1	0	III	None	1st dose: cisplatin 80% 2nd dose: cisplatin 50%, 5-FU 50%	-	23.7 +	23.7 +
9	75	M	Mt	SCC	3	2	0	III	None	1st dose: cisplatin 80% 2nd dose: cisplatin no application	-	27.0 +	27.0 +
10	72	F	Ut Mt	SCC	2	2	0	III	None	-	-	2.8 +	2.8 +
11	58	M	Mt Ut	SCC	3	2	0	III	None	-	-	17.9 +	17.9 +
12	61	M	Ut Ce	SCC	3	3	0	IVA	None	-	Lymph nodes	8.4	10.8 +

Ce, cervical esophagus; Ae, abdominal esophagus; Ut, upper thoracic esophagus; Mt, middle thoracic esophagus; Lt, lower thoracic esophagus; SCC, squamous cell carcinoma; Adeno, adenocarcinoma; PR, partial response; CR, complete response; PD, progressive disease; SD, stable disease; RFS, relapse-free survival; OS, overall survival; M, male; F, female. RFS and OS of censored cases are marked with “+”.

Table SII. Characteristics and treatment of patients in group B.

Patient	Age, years	Sex	Tumor location	Histopathology	T	N	M	Clinical stage	Delayed start of 2nd dose	Dose reduction	Recurrence	RFS, months	OS, months
1	67	M	Mt	SCC	3	0	0	II	None	-	Liver	6.7	8.2
2	67	M	Mt	SCC	3	2	0	III	2nd dose: 4-day delay	1st dose: cisplatin 75%	Bone	6.7	19.4 +
3	49	F	Mt	SCC	3	0	0	II	None	-	-	15.7 +	15.7 +
4	59	M	Mt Lt	SCC	4	2	0	III	None	-	-	21.2 +	21.2 +
5	53	F	Mt	SCC	3	0	0	III	None	-	-	18.8 +	18.8 +
6	68	M	Ut	SCC	3	1	0	III	None	2nd dose: cisplatin 75%	Lymph nodes	7.9	11.1
7	68	M	Ut	SCC	3	2	0	III	None	1st and 2nd doses: cisplatin 75%	-	15.2 +	15.2 +
8	74	F	Mt	SCC	3	1	0	III	None	-	-	11.1 +	11.1 +
9	59	M	Ut Mt	SCC	4	1	0	III	2nd dose: 8-day delay	-	Peritoneal dissemination	10.8	22.5
10	66	M	Lt	SCC	3	1	0	III	None	-	Liver and lung	6.7	7.8
11	74	M	Ut	SCC	3	0	0	II	None	1st and 2nd doses: cisplatin no application	-	38.8 +	38.8 +
12	72	M	Ut	SCC	3	1	0	III	None	-	-	43.0 +	43.0 +
13	71	M	Mt Lt	SCC	3	2	0	III	None	-	-	-	5.5 +
14	73	M	Ut	SCC	3	2	0	III	None	2nd dose: cisplatin 50%	-	8.5	8.5
15	73	M	Mt Lt	SCC	3	2	0	III	None	1st and 2nd doses: cisplatin 50%	Lung	21.5 +	21.5 +
16	68	M	Mt Ut	SCC	3	2	0	III	None	-	-	18.5 +	18.5 +
17	48	M	Lt	SCC	3	2	0	III	None	-	-	7.7 +	7.7 +

Ut, upper thoracic esophagus; Mt, middle thoracic esophagus; Lt, lower thoracic esophagus; SCC, squamous cell carcinoma; PR, partial response; CR, complete response; PD, progressive disease; SD, stable disease; RFS, relapse-free survival; OS, overall survival; M, male; F, female. RFS and OS of censored cases are marked with “+”.